Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:starting:physician:reluctant [04.29.2019]
sallieq [Read more]
home:starting:physician:reluctant [04.30.2019] (current)
sallieq [Specific research]
Line 272: Line 272:
 the volume of larger atherosclerotic plaques (({{pubmed>​long:​19124398}})), ​ PMID 19124398 the volume of larger atherosclerotic plaques (({{pubmed>​long:​19124398}})), ​ PMID 19124398
  
 +Observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris. ​ (({{pubmed>​long:​20202514}})) ​ PMID 20202514
 +
 +This study showed that olmesartan reduces angiotensin II and aldosterone levels more effectively than azilsartan. ​ (({{pubmed>​long:​27086671}})) ​  PMID 27086671 ​
  
 improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>​long:​25891757}})), ​ PMID 25891757 improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>​long:​25891757}})), ​ PMID 25891757
home/starting/physician/reluctant.txt · Last modified: 04.30.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.